Axsome Therapeutics (AXSM) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 114.4% versus a gain of 43.3%. Over five years, PTGX leads with a +364.1% price change compared with +324.1% for AXSM. Protagonist Therapeutics is the larger company by market cap ($9.30 billion vs $8.82 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs -89.4%).
Axsome Therapeutics converts more of its revenue into profit, with a net margin of -28.7% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | PTGX |
|---|---|---|
| Share price | $168.35 | $143.73 |
| Market cap | $8.82B | $9.30B |
| 1-day change | -1.02% | +2.73% |
| YTD return | -6.88% | +64.56% |
| 1-year return | +43.27% | +114.39% |
| 5-year return | +324.14% | +364.09% |
| P/E ratio (TTM) | — | 139.54 |
| Forward P/E | 35.80 | — |
| EPS (TTM) | $-3.74 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $46.02M |
| Revenue growth (YoY) | +65.55% | -89.41% |
| Net income (latest FY) | $-183.17M | $-130.15M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | -343.63% |
| Net margin | -28.69% | -282.83% |
| 52-week high | $260.19 | $160.81 |
| 52-week low | $119.20 | $65.75 |
| Distance from 52-week high | -35.30% | -10.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.07% | +21.54% |
| Average volume | 712.30K | 623.06K |
| Shares outstanding | 52.38M | 64.71M |
| Employees | 1,346 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed AXSM by 71.1 percentage points over the past year.
- Axsome Therapeutics is more profitable, keeping -28.7 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs -89.41%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
AXSM vs PTGX FAQ
Which is bigger, Axsome Therapeutics or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.30B compared with $8.82B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or PTGX?
PTGX returned +114.39% over the past 12 months, compared with +43.27% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.